Develops treatments for pulmonary hypertension and other cardiovascular diseases.
Tenax Therapeutics, Inc. is a specialized pharmaceutical company focused on the development and commercialization of treatments for cardiovascular and pulmonary diseases across the United States and Canada. The company's robust pipeline includes TNX-103 and TNX-102 (levosimendan), both of which have completed Phase II clinical trials. These therapies are targeted for patients suffering from pulmonary hypertension associated with heart failure with preserved ejection fraction and related pulmonary hypertension. Additionally, Tenax Therapeutics is advancing TNX-201 (imatinib), a tyrosine kinase inhibitor aimed at treating pulmonary arterial hypertension.
Originally founded as Oxygen Biotherapeutics, Inc., the company rebranded as Tenax Therapeutics, Inc. in September 2014 to better reflect its strategic focus on therapeutic advancements in cardiovascular and pulmonary medicine. With a legacy dating back to 1967 and headquartered in Morrisville, North Carolina, Tenax Therapeutics continues to drive innovation in the field, leveraging decades of experience and scientific expertise to address critical unmet medical needs.
Through its commitment to research and development, Tenax Therapeutics aims to introduce effective therapies that improve patient outcomes and quality of life. By advancing its pipeline and collaborating with healthcare partners, the company remains dedicated to making significant contributions to the treatment landscape for cardiovascular and pulmonary diseases.